Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

Have you ever found yourself engaging in slow-motion recreational activities? In the unlikely event that this is the case, ...

On Friday, more than 100 students and trainee researchers from the Texas Tech University Health Sciences Center presented ...

Oklahoma City-based OU Health has appointed Azeemuddin Ahmed, MD, as clinical service chief of emergency medicine and founding chair of the newly created department of emergency medicine at the ...

AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. Details of the poster are as follows: Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of ...

The head of a police community group in one of NYC’s most Jewish neighborhoods tore down posters of missing Israeli hostages, disturbing footage shows. Robert Josman, longtime president and ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

I understand there’s an ongoing rift between James Dolan and Adam Silver. I get it. But every day, the commissioner should be rooting for the Knicks. And not just because of their market appeal ...

Just hours before the release of Salman Khan's Sikandar trailer, the makers unveiled a brand-new poster. The poster showcases the film's stellar ensemble cast, with the movie set to release on Eid.

Plan now to have your poster included in the 2025 Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series. Submit your abstract here. Our virtual conference allows you to ...

He got into medicine at Monash University, but continued playing footy casually, first at the school old boys in the amateurs, and then when medical placements took him to Sale and Mildura ...

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down ...